Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
DarioHealth Corp Market Cap
The DarioHealth Corp (DRIO) share price is expected to increase by 343.04% over the next year. This is based on calculating the average 12-month share price estimate provided by 3 stock analysts who have covered DRIO. Price targets range from $2 at the low end to $5 at the high end. The current analyst consensus for DRIO is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 3 Wall Street analysts have assignedDRIO 3 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect DarioHealth Corp to buy. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on DRIO. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of DRIO.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| David Grossman Stifel | Buy | $4 | Maintains | Apr 1, 2024 |
| Ben Haynor Alliance Global Partners | Buy | $4.1 | Maintains | Aug 11, 2023 |
Stifel | Buy | Maintains | Jul 25, 2023 | |
| Alexander Nowak Craig-Hallum | Buy | $8 | Maintains | May 12, 2023 |
| Ben Haynor Alliance Global Partners | Buy | $7.5 | Maintains | Nov 16, 2022 |
| Nathan Weinstein Aegis Capital | Buy | $15 | Maintains | Aug 18, 2022 |
| Charles Rhyee Cowen & Co. | Outperform | $14 | Maintains | Aug 16, 2022 |
| Nathan Weinstein Aegis Capital | Buy | $20 | Maintains | May 16, 2022 |
| Charles Rhyee Cowen & Co. | Outperform | $18 | Maintains | May 16, 2022 |
Alliance Global Partners | Buy | Upgrade | May 13, 2022 | |
| Nathan Weinstein Aegis Capital | Buy | $25 | Maintains | Jan 26, 2022 |
| Nathan Weinstein Aegis Capital | Buy | $28 | Maintains | Aug 19, 2021 |
Cowen & Co. | Outperform | Initiates | Apr 22, 2021 | |
Stifel | Buy | Initiates | Mar 23, 2021 | |
| Nathan Weinstein Aegis Capital | Buy | $35 | Maintains | Feb 8, 2021 |
Craig-Hallum | Buy | Maintains | Nov 25, 2020 | |
ThinkEquity | Buy | Initiates | Nov 25, 2020 | |
Rodman & Renshaw | Buy | Initiates | Nov 25, 2020 | |
Chardan Capital | Buy | Initiates | Nov 25, 2020 | |
Aegis Capital | Buy | Initiates | Nov 25, 2020 |
When did it IPO
2016
Staff Count
276
Country
United States
Sector/Industry
Healthcare/Health Information Services
CEO
Mr. Erez Raphael
Market Cap
$23.0M
In 2023, DRIO generated $20.4M in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that DRIO's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Thu, 21 Nov 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - DarioHealth Corp. expects 25 new client signings in 2024, a 35% increase from 2023. Four contracts with self-insured employers will start in Q1 2025.
Why It Matters - DarioHealth's expected 35% client growth and new contracts signal strong revenue potential and business momentum, which may boost investor confidence and drive stock performance.
Sat, 09 Nov 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - DarioHealth Corp. (NASDAQ: DRIO) will hold its Q3 2024 results conference call on November 7, 2024, at 8:30 AM ET. Participants include CEO Erez Raphael and CCO Steven Nelson.
Why It Matters - DarioHealth's Q3 2024 results call could provide insights into financial performance, growth strategies, and market positioning, impacting investor sentiment and stock valuation.
Thu, 07 Nov 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Q3 revenue reached $7.42 million, up 18.7% from Q2 2024 and 111% year-over-year, fueled by B2B2C revenue growth.
Why It Matters - Strong revenue growth signals robust business performance, attracting investor interest and potentially boosting stock prices. Positive momentum in B2B2C expansion suggests future profitability.
Thu, 07 Nov 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - DarioHealth Corp. (DRIO) reported a quarterly loss of $0.13 per share, better than the estimated loss of $0.18, and improved from a loss of $0.49 per share a year prior.
Why It Matters - DarioHealth's smaller-than-expected quarterly loss signals improving financial health, potentially boosting investor confidence and affecting stock performance positively.
Mon, 04 Nov 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - DarioHealth Corp. has secured a subscription contract with a major U.S. pharma client, shifting to recurring revenue and enhancing patient engagement for a new psoriasis drug.
Why It Matters - Dario's shift to recurring subscription fees enhances revenue stability and growth potential, while its collaboration with a major pharma client could expand market reach and patient engagement.
Wed, 30 Oct 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - DarioHealth Corp. secured its eighth health plan contract, expanding its Medicaid offerings with immediate revenue contributions from its cardiometabolic solutions.
Why It Matters - DarioHealth's new contract adds immediate revenue and expands its presence in the Medicaid market, signaling growth potential and increased market share in digital health.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
